A study of "Sleep and MS" for the treatment of fatigue
Previous studies have found an association between sleep disorders and fatigue in patients suffering from multiple sclerosis (MS). Therefore, it is safe to assume that fatigue is at least one possible cause of an existing sleep disorder. Our latest study looks further into this connection by investigating whether treating sleep disorders in patients with MS also alleviates fatigue.
In this respect, MS patients that have been diagnosed with a sleep disorder in the sleep lab are randomly assigned to either a treatment group or a control group. The treatment group receives sleep medication therapy during the entire study. The control group will continue with the previous treatment for fatigue and will only receive sleep medication therapy six months later, once the study has been completed. Women and men between the ages of 18 and 75 suffering from any form of multiple sclerosis can take part. The study will be carried out at the NCRC in Berlin, Mitte. Each participant will receive a one-time remuneration.
Title of study: Effects of sleep medication treatment on fatigue in multiple sclerosis patients with elevated values in the Modified Fatigue Impact Scale (> 34) or the Pittsburgh Sleep Quality Index Questionnaire (> 5) as part of a prospective controlled trial study (sleep and MS)
Participation in the study entails the following:
- There will be an initial question and discussion session to clarify and provide information which will include a physical examination. In addition, some written questionnaires will be completed.
- The diagnostics of the sleep medication therapy will take place during a two night stay in the sleep laboratory and will include multiple sleep latency tests (MSLT) during the day
- Patients of the therapy group will also be taking the sleep medication therapy. This medication can vary considerably, depending on the kind of sleep disorder and overall medical condition.
- A final doctor's examination takes place six months after the start of the sleep medication therapy or the waiting phase. All patients will fill out additional questionnaires at that time.
Contact for patients interested in the study:
030 - 450 539 040
030 - 450 539 773
Management for the study is carried out by:
Prof. Dr. Friedemann Paul (AG Klinische Neuroimmunologie, NCRC) and Christian Veauthier, M.D. (Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie / Interdisciplinary Center for Sleep Medicine Zentrum; CCM) Charité - Universitätsmedizin Berlin